No Data
Express News | 【Change Report】 Mr. Akihiro Date reported a decrease in the shareholding ratio of Birdman (7063.JP) to 4.42%.
Kakaku.com ETC [Stocks with intriguing potential seen from Volume changes]
Closing price comparison with the previous day Volume * <9776> Sapporo 100,552,198,400 * <9240> Delivery Consultant 34,512,550,700 * <6074> JSS 41,514,134,400 * <6822> Oi Electric 273,219,884,000 * <3758> Aeria 25,124,654,400 * <4260> Hybrid Tech 46,769,202,300 * <7140> Petgo 89,129,135,400 * <4076> C.N.S 151,413,269,400 * <3
Express News | [Change Report] Akihiro Date reported a decrease in Shareholding in Birdman (7063.JP) to 5.46%.
Birdman ETC [Stocks with interesting features seen from Volume changes]
Closing price and changes from the previous day Volume * <7063> Birdman 2,316,718,200 * <149A> Shinka 1,074,150,153,700 * <3238> Central General 4,791,138,800 * <1560> Bursa KLCI 5,180,301,068 * <9561> Glad Cube 89,126,375,200 * <9791> Biken Tech 1,012,653,1900 * <8707> Iwai Koss Corp 256,049,353,200 * <9658> Bizi Tai Show 269,314,162,800
Individual stock information.
Kei Pharma <4896.T> is under a stop-high buy order. Keio University School of Medicine, which conducts joint research with the company, announced new research findings on regenerative medicine targeting subacute spinal cord injuries, one of the candidates in the development pipeline for regenerative medicine, on the weekend of the 21st. In the clinical study of regenerative medicine using iPS cell-derived neural progenitor cells, improvements were observed in two out of four patients. Saifuse <4892.T> Tokyo Stock Exchange is utilizing Margin Trading.
Requio Pharmaceuticals, GDH and others.
＜3133＞ Kaifan Birdman has signed a business consignment contract with ＜7063＞. ＜4169＞ Enechange recorded a subsidy benefit of 0.041 billion yen as non-operating income. ＜4437＞ GDH has increased the Dividends, with a year-end distribution of 4.00 yen per share, up from 3.00 yen. ＜4475＞ HENGGE has established a joint venture (consolidated subsidiary) in the USA. ＜4579＞ Raquoia Pharmaceutical has entered into a capital and business partnership agreement with HK inno.N Corporation (South Korea), through the issuance of new shares via third-party allotment (2.59 million).
